Mirae Asset Global Investments Co. Ltd. Buys 559 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 31.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,330 shares of the company’s stock after acquiring an additional 559 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Nurix Therapeutics were worth $54,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in NRIX. Driehaus Capital Management LLC bought a new stake in Nurix Therapeutics during the second quarter worth approximately $26,778,000. Redmile Group LLC boosted its position in shares of Nurix Therapeutics by 37.7% during the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after buying an additional 1,226,497 shares during the period. Samlyn Capital LLC purchased a new position in shares of Nurix Therapeutics during the second quarter valued at approximately $12,177,000. Ikarian Capital LLC purchased a new position in shares of Nurix Therapeutics during the first quarter valued at approximately $4,410,000. Finally, Candriam S.C.A. boosted its position in shares of Nurix Therapeutics by 30.5% during the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after buying an additional 272,136 shares during the period.

Nurix Therapeutics Price Performance

Shares of NASDAQ NRIX opened at $25.43 on Wednesday. The company has a 50 day simple moving average of $24.21 and a 200-day simple moving average of $20.42. The company has a market capitalization of $1.80 billion, a P/E ratio of -8.74 and a beta of 2.20. Nurix Therapeutics, Inc. has a 1 year low of $4.96 and a 1 year high of $27.60.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The firm had revenue of $12.59 million during the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. As a group, research analysts expect that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Christine Ring sold 9,870 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.01, for a total transaction of $246,848.70. Following the completion of the transaction, the insider now owns 24,592 shares of the company’s stock, valued at approximately $615,045.92. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Nurix Therapeutics news, insider Christine Ring sold 9,870 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.01, for a total value of $246,848.70. Following the completion of the transaction, the insider now owns 24,592 shares of the company’s stock, valued at $615,045.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the completion of the transaction, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at $781,870.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 57,321 shares of company stock valued at $1,414,409. Company insiders own 9.80% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on NRIX. Barclays boosted their target price on Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. Truist Financial began coverage on Nurix Therapeutics in a research report on Wednesday, July 31st. They set a “buy” rating and a $36.00 target price for the company. Oppenheimer boosted their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. Stephens reiterated an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a report on Monday, October 14th. Finally, Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price target for the company. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.